VCTX211
VCTX211-101
Phase 1 other terminated
Quick answer
VCTX211 for Diabetes Mellitus is a Phase 1 program (other) at CRISPR Therapeutics AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- CRISPR Therapeutics AG
- Indication
- Diabetes Mellitus
- Phase
- Phase 1
- Modality
- other
- Status
- terminated